Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.33 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | DRD1 | P21728 | 3/20 | 0.97 |
| ▸ | DRD4 | P21917 | 3/20 | 0.97 |
| ▸ | DRD5 | P21918 | 3/20 | 0.97 |
| ▸ | DRD3 | P35462 | 3/20 | 0.97 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RAD52 | P43351 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | APEX1 | P27695 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10923362 | 0.98 | DRD2 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Bromide SCHEMBL11283750 | 0.82 | DRD2 (0.67) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4790581 | 0.79 | DRD2 (0.68) | DRD2DRD1DRD4DRD5DRD3 | |
| Bromide SCHEMBL7380398 | 0.79 | DRD2 (0.65) | DRD2DRD1DRD4DRD5DRD3 | |
| Bromide SCHEMBL10923497 | 0.78 | DRD2 (0.62) | DRD2DRD1DRD4DRD5DRD3 | |
| Skf-89124A SCHEMBL7382070 | 0.78 | DRD2 (0.97) | DRD2DRD1DRD4DRD5DRD3 | |
| Bromide SCHEMBL7384529 | 0.78 | DRD2 (0.64) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL10923131 | 0.77 | DRD2 (0.63) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL7383689 | 0.76 | DRD2 (0.65) | DRD2DRD1DRD4DRD5DRD3 | |
| Skf-89124A SCHEMBL2914813 | 0.76 | DRD2 (1.00) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| CN-101636379-A | Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases | ASTRAZENECA AB | 2010-01-27 | — | — | CN | disclosed |
| EP-2094646-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-4588740-A | Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0046666-B1 | 2(3H)-INDOLONES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0113964-A1 | 4-Aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4452808-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-06-05 | — | — | US | disclosed |
| US-4414224-A | 4-AMINO OR SUBSTITUTED AMINO-7-HYDROXY-2-(3H)-INDOLONES | SMITHKLINE BECKMAN CORPORATION (US) | 1983-11-08 | — | — | US | disclosed |
| EP-0046666-A1 | 2(3H)-indolones, process for their preparation and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1982-03-03 | — | — | EP | disclosed |
| US-4314944-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE AGENTS | SMITHKLINE CORPORATION (US) | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | CHRM2 6/4885HTR1A 293/4885ADRA2A 13/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | CHRM2 10/4885HTR1A 114/4885ADRA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.